신경혈관 중재술 기기 시장 : 제품 유형, 적응증, 시술 유형, 최종 사용자별 예측(2026-2032년)

The Neurovascular Intervention Devices Market is projected to grow by USD 7.14 billion at a CAGR of 6.69% by 2032.

The neurovascular intervention devices landscape is expanding as stroke and intracranial aneurysm care moves from pharmacologic-only treatment toward time-sensitive, image-guided endovascular therapy. The World Stroke Organization and Global Burden of Disease data identify stroke as one of the leading global causes of death and long-term disability, with more than 12 million new strokes and over 6 million stroke-related deaths reported annually. This disease burden supports sustained clinical demand for stent retrievers, aspiration catheters, embolization coils, flow diverters, intrasaccular devices, neurovascular stents, guidewires, microcatheters, balloon catheters, and vascular access systems.

Clinical adoption is underpinned by randomized evidence showing that mechanical thrombectomy improves functional outcomes in eligible large vessel occlusion stroke, including selected patients treated beyond the traditional early treatment window when advanced imaging confirms salvageable brain tissue. Hospitals, device manufacturers, clinicians, and payers are therefore prioritizing faster diagnosis, organized stroke networks, and neurovascular devices that improve deliverability, recanalization, procedural safety, and workflow efficiency.

Transformative Shifts in the Neurovascular Device Landscape

The neurovascular intervention devices landscape is being reshaped by the convergence of minimally invasive therapy, advanced neuroimaging, and formalized stroke systems of care. Mechanical thrombectomy has shifted acute ischemic stroke treatment toward rapid endovascular access for appropriate large vessel occlusion cases, while newer aneurysm technologies such as flow diversion, intrasaccular embolization, and adjunctive stenting are broadening treatment options for complex, bifurcation, and wide-neck intracranial aneurysms.

Regulatory and procurement expectations are also changing. The European Medical Device Regulation has raised clinical evidence, risk management, and post-market surveillance requirements, while U.S. FDA pathways continue to emphasize safety, performance, labeling accuracy, and real-world monitoring. At the same time, hospitals are consolidating neurointerventional services into high-volume comprehensive stroke centers and thrombectomy-capable networks, placing greater value on device compatibility, physician training support, inventory reliability, imaging integration, and measurable clinical outcomes.

Cumulative Impact of Artificial Intelligence in Neurovascular Care

Artificial intelligence is creating a cumulative impact across the neurovascular care pathway rather than acting as a single-point technology. FDA-authorized AI-enabled radiology tools increasingly support detection and triage of large vessel occlusion, intracranial hemorrhage, and perfusion abnormalities, helping care teams shorten door-to-image, image-to-notification, and image-to-intervention decision cycles in acute stroke workflows.

Beyond triage, AI is being applied to vessel segmentation, clot characterization, aneurysm measurement, procedural planning, robotics research, case prioritization, quality reporting, and post-market performance analytics. The strongest commercial opportunities will come from validated AI that integrates with PACS, stroke communication platforms, electronic health records, and cath lab workflows. Industry leaders must also address algorithmic bias, cybersecurity, explainability, data governance, and evidence generation because AI performance can vary across scanners, imaging protocols, patient populations, and clinical settings.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Regions

North America remains a high-adoption region for neurovascular intervention devices due to mature stroke center networks, broad availability of CT angiography and perfusion imaging, established reimbursement channels, and strong participation in neurovascular clinical research. Europe combines sophisticated neurointerventional practice with stricter evidence expectations under the Medical Device Regulation, creating opportunities for clinically differentiated thrombectomy, embolization, and aneurysm treatment technologies that can demonstrate safety, durability, usability, and health-system value.

Asia-Pacific carries a substantial share of the global stroke burden, with China, India, Japan, South Korea, and Australia shaping demand through different combinations of public investment, specialist availability, imaging infrastructure, and reimbursement maturity. Latin America is led by Brazil and Mexico but remains uneven in access to thrombectomy-capable hospitals and trained neurointerventional specialists. The Middle East, particularly advanced Gulf health systems, is investing in tertiary hospitals, digital health, and stroke service modernization, while Africa represents a long-term access opportunity constrained by limited advanced imaging capacity, specialist shortages, referral delays, and affordability barriers.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are moving toward stronger stroke referral pathways and greater adoption of endovascular stroke treatment, but implementation differs widely between Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines because of reimbursement models, urban-rural access, hospital infrastructure, and interventional workforce capacity. GCC countries are investing in tertiary care hospitals, digital health infrastructure, specialist recruitment, and international clinical standards, which supports demand for premium neurovascular technologies in centers of excellence.

The European Union is defined by MDR compliance, stronger clinical evidence expectations, coordinated health technology assessment trends, and sophisticated hospital procurement. BRICS countries represent major procedure-volume potential because of high stroke burden and expanding hospital capacity, but pricing, local manufacturing, public purchasing, and reimbursement inclusion are decisive. G7 markets remain central to innovation, guideline development, clinical trial leadership, and early adoption of advanced neurovascular devices, while NATO countries increasingly frame medical supply resilience, secure procurement, and domestic capacity as healthcare security priorities.

Key Country Insights Across Major Neurovascular Markets

The United States is a leading innovation and adoption hub, supported by comprehensive stroke center certification, FDA-reviewed neurovascular devices, advanced imaging access, and strong clinical trial infrastructure, while Canada emphasizes equitable access across provincial health systems and regionalized stroke care pathways. Mexico and Brazil are expanding neurointerventional capability, though access to mechanical thrombectomy and aneurysm embolization remains concentrated in major urban hospitals and private or tertiary public centers.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature specialist networks with increasing scrutiny of clinical evidence, procurement value, and post-market performance, while Russia presents demand shaped by public investment, regional infrastructure differences, and access variability. China is scaling domestic and imported neurovascular technologies alongside high stroke volumes and expanding hospital capabilities; India offers substantial long-term clinical need but remains highly price-sensitive with uneven access outside large metropolitan centers. Japan and South Korea are advanced adopters with strong imaging infrastructure, specialist capacity, and aging populations that increase cerebrovascular disease management needs, while Australia benefits from organized stroke networks, aeromedical referral pathways, and telehealth-enabled coordination across geographically dispersed communities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-backed differentiation in neurovascular intervention devices. Products that improve first-pass reperfusion, reduce procedure time, enhance trackability through tortuous anatomy, lower complication risk, and demonstrate durable aneurysm occlusion will command stronger clinical attention than devices positioned only on incremental design changes.

Manufacturers should build integrated offerings around physician training, AI-enabled workflow partnerships, inventory planning, and real-world evidence generation. Commercial teams should segment markets by stroke network maturity, reimbursement readiness, imaging access, and specialist density. In emerging markets, affordability, local partnerships, physician education, service support, and reliable supply chains are critical. Across all regions, leaders should prepare for tighter post-market surveillance, cybersecurity expectations for connected systems, and stronger proof of clinical and health-economic value.

Research Methodology

This executive summary is based on a structured methodology combining verified secondary research, regulatory review, clinical literature assessment, and market triangulation. Sources considered include peer-reviewed stroke and neurointervention studies, World Stroke Organization and Global Burden of Disease findings, FDA and European regulatory information, hospital care pathway standards, reimbursement references, clinical guideline documents, and publicly available healthcare infrastructure indicators.

Insights were validated through cross-checking of disease burden, technology adoption drivers, regulatory trends, care delivery models, and regional healthcare infrastructure indicators. The analysis emphasizes evidence-supported directionality rather than unsupported numerical forecasts, ensuring that conclusions reflect clinically grounded and commercially relevant developments in neurovascular intervention devices.

Conclusion

Neurovascular intervention devices are becoming central to modern stroke and intracranial aneurysm care as health systems prioritize faster diagnosis, minimally invasive treatment, and measurable patient outcomes. The landscape is supported by a large cerebrovascular disease burden, proven thrombectomy benefits in selected large vessel occlusion patients, continued aneurysm device innovation, and growing use of artificial intelligence to accelerate imaging triage and treatment coordination.

Competitive advantage will depend on clinical evidence, procedural performance, regulatory readiness, supply reliability, and the ability to support organized stroke systems across both mature and emerging healthcare markets. Organizations that align product innovation with real-world workflow, physician training, data-driven quality improvement, and access expansion will be best positioned for sustainable growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neurovascular Intervention Devices Market, by Product Type

• 7.1. Embolic Agents
  • 7.1.1. Liquid Embolics
  • 7.1.2. Particulate Embolics
• 7.2. Flow Diverters
  • 7.2.1. Pipeline Embolization Device
  • 7.2.2. Surpass Flow Diverter
• 7.3. Microcatheters
  • 7.3.1. Hydrophilic Coated
  • 7.3.2. Polymer Coated
• 7.4. Neurovascular Coils
  • 7.4.1. Detachable Coils
  • 7.4.2. Pushable Coils
• 7.5. Stents
  • 7.5.1. Balloon Mounted
  • 7.5.2. Self Expanding
• 7.6. Thrombectomy Devices
  • 7.6.1. Aspiration Devices
  • 7.6.2. Stent Retriever

8. Neurovascular Intervention Devices Market, by Indication

• 8.1. Aneurysm
• 8.2. Arteriovenous Malformation
• 8.3. Stroke

9. Neurovascular Intervention Devices Market, by Procedure Type

• 9.1. Embolization
• 9.2. Flow Diversion
• 9.3. Thrombectomy

10. Neurovascular Intervention Devices Market, by End User

• 10.1. Ambulatory Centers
• 10.2. Clinics
• 10.3. Hospitals

11. Neurovascular Intervention Devices Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Neurovascular Intervention Devices Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Neurovascular Intervention Devices Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Acandis GmbH
• 15.3. Achieva Medical Co Ltd
• 15.4. Asahi Intecc Co Ltd
• 15.5. Balt Group
• 15.6. Boston Scientific Corporation
• 15.7. Cerus Endovascular Ltd
• 15.8. Evasc Neurovascular Enterprises
• 15.9. Imperative Care Inc
• 15.10. InspireMD Inc
• 15.11. Integer Holdings Corporation
• 15.12. Kaneka Corporation
• 15.13. Lepu Medical Technology Beijing Co Ltd
• 15.14. Medtronic plc
• 15.15. Merit Medical Systems Inc
• 15.16. MicroPort Scientific Corporation
• 15.17. NeuroSafe Medical Co Ltd
• 15.18. NeuroVasc Technologies Inc
• 15.19. Penumbra Inc
• 15.20. Perflow Medical Ltd
• 15.21. Rapid Medical Ltd
• 15.22. Shanghai HeartCare Medical Technology Corporation Ltd
• 15.23. Shape Memory Medical Inc
• 15.24. Stryker Corporation
• 15.25. Teleflex Incorporated
• 15.26. Terumo Corporation
• 15.27. Vesalio LLC
• 15.28. Wallaby Medical
• 15.29. Zylox-Tonbridge Medical Technology Co Ltd